In preclinical studies using an AML model, combining azacytidine with CD47 blockade resulted in enhanced macrophage‐mediated phagocytosis in vitro and enhanced antitumor activity in vivo.19 This evidence concerns the gene CD47 and acute myeloid leukemia.